Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. You are currently on the Bayer global website. About. Stock Market | FinancialContent Business Page to proceed to electronic versions of these materials. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. us, How
NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Nextpoint - Overview, News & Competitors | ZoomInfo.com Aktis Oncology Announces $72M Series A Financing To Advance +49 30 468 1111, Alfred-Nobel-Str. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Apellis' blindness drug approved by FDA; Moderna strikes gene-editing Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. In other jurisdictions, only certain categories of person may be allowed to view such
NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. sufficient information on the terms of the offer and any securities to be offered so as to enable an
For more information, go to www.bayer.com. States, Australia, Canada or Japan. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or
R&D expenses before special items amounted to 5.3 billion euros. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together
For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Trends, Growing
As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. We do not accept any responsibility or liability for these policies and procedures. Member State, except that an offer to the public in such Relevant Member State of any securities may
We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Your computer and mobile devices when you visit our Site. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Scott Chappel - Executive Partner at MPM Capital | The Org Bachelor of Science required, Masters of Science preferred. With our distinctive knowledge of people, animals and plants,
& Solutions, Development
51373 Leverkusen
Stock Market | Financial News | myMotherLode.com Drs. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Neither this announcement nor anything contained herein shall form the basis of,
The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Requests may be made only once a year and are free of charge. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. This announcement is an advertisement and does not, under any
Republic, Dominican
Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. There will be no public
Bayer is an innovation company with a more than 150-year history. Meeting & Agenda, Stockholders'
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical for Prescription Medicine in Europe, Counterfeits in
Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. 1 Wei Y, Ren X, Galbo PM Jr, et al. Tony Arulanandam | Cytovia Therapeutics KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Africa, Sri
Learn more about
& Rewards, Values
Water
State. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. At the same time, the Group aims to increase its earning power and create value through innovation and growth. These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. News, Conditions of
Financial
Use, Privacy
The final prospectus, when published, will be
Safety, Climate
NextPoint Therapeutics Announces $80 Million Series B Financing co-led The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Viewing the materials you seek to access may not be lawful in certain
Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. +49 214 30 1, Mllerstrae 178
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Zhao R, Chinai JM, Buhl S, et al. . NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. NextPoint Therapeutics Announces $80 Million Series B Financing co-led NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Our innovative approach integrates foundational. Related Persons. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. Consensus, Return
Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. The financing will be used to advance NextPoint . The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. on
NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Leverkusen, ESG Ratings and
In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Stock Market | Finance Demand, Breakthroughs
public offer of the securities in the United States. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Cancer Immunol Res. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. Homepage - NextPoint Therapeutics Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Headquarters, Costa
Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). Sanofi Ventures is the corporate venture capital arm of Sanofi. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). To learn more, visit nextpointtx.com. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. By clicking on the I AGREE button, I certify that I am not located
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Neither this announcement nor anything contained
CAMBRIDGE, Mass. our employees, International
Features
The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge Previous study start-up and clinical monitoring experience desired. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). NextPoint Therapeutics - LabCentral | Cambridge, MA the world. Bayer Global
Bayer, Meet
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. archive, Shareholder
This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. NEXTPOINT THERAPEUTICS, INC. :: Massachusetts (US) - OpenCorporates Rica, Czech
As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. application, Your
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Viewing the materials you seek to access may not be lawful in certain jurisdictions. Governance, Sustainability
Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to Stewardship, Pharmaceuticals
Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Your computer and mobile devices when you access our Site. a Glance, Latest
616 followers 500+ connections. combating counterfeits, Bayer CapSeal
Potential, Leading
Furthermore, where permissible, we may charge for this service. & Impact, Benefits
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Distances, Work
Protection, Environmental
Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. In this article, I lay out what I see as three NextPoint - MPM Capital Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. Locations, Your
Expertise, Our
The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. R&D expenses before special items amounted to 5.3 billion euros. Deforestation and Forest Degradation, Postion
Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Any person who wishes to view these materials must first satisfy themselves that they are
By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Council, Stakeholder
We also use cookies and similar technologies for purposes of marketing and advertising. designed to prevent, alleviate and treat diseases. 4. Hub Langenfeld, Accelerate
Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. R&D expenses before special items amounted to 5.3 billion euros. Fighting Counterfeit Drugs, New Safety
NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Kong, China, Ireland,
Supply Chain Management Trainee Program, International
NextPoint Therapeutics Announces $80 Million Series B Financing co-led any facility of a national securities exchange of the United States and the tender offer cannot be
Bayer CapSeal App, Better Harvests
Zealand, Palestinian
In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. 2021 Jul 9;6(61):9792. 'We're not a vant': Axovant seeks to forget the past as the company China, United
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Any person who is not a relevant person should not act or rely on the
Our innovative approach integrates foundational. Bayers leadership in agriculture provides tailored solutions
Our Privacy Notice does not apply to Third-Party Sites. In other
About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Investing in a stronger future - for our shareholders, and
These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Looking for a job in an innovative company? these pages, please confirm that you are a medical journalist and that you would like to accredit to
Life & Challenges, Reputation
They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Avoid Counterfeits, Bayers role in
Statement, Cookie
Stock Market | Pittsburgh Post-Gazette For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). NextPoint Therapeutics, Inc. hiring Associate Director/Director We may update this Privacy Notice from time to time. NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable.